Title: Ustekinumab trough levels predicting laboratory and endoscopic remission in patients
with Crohn’s disease
Version: 1 Date: 19 Jan 2022
Reviewer's report:
The authors investigated ustekinumab pharmacokinetics in a single-center cohort of 28 Crohn’s
disease patient. This is another association study between TDM and clinical and endoscopic
outcomes in IBD. Many important data are missing in the methods section and the endoscopic
scoring system used is not adapted for assessing CD activity out of the screening for
postoperative recurrence.
It is not understandable why the authors have chosen the Rutgeerts score for assessing CD
endoscopic activity as this score was only made for postoperative recurrence. I suggest to use
CDEIS or SES-CD as recommended by all CD guidelines and redo the statistical analysis.
What were the selection criteria for participating in this study?
Can you give some information about the study design: at least when and how these patients
have been recruited?
Title: Ustekinumab trough levels predicting laboratory and endoscopic remission in patients
with Crohn’s disease
Version: 1 Date: 19 Jan 2022
Reviewer's report:
The authors investigated ustekinumab pharmacokinetics in a single-center cohort of 28 Crohn’s
disease patient. This is another association study between TDM and clinical and endoscopic
outcomes in IBD. Many important data are missing in the methods section and the endoscopic
scoring system used is not adapted for assessing CD activity out of the screening for
postoperative recurrence.
It is not understandable why the authors have chosen the Rutgeerts score for assessing CD
endoscopic activity as this score was only made for postoperative recurrence. I suggest to use
CDEIS or SES-CD as recommended by all CD guidelines and redo the statistical analysis.
What were the selection criteria for participating in this study?
Can you give some information about the study design: at least when and how these patients
have been recruited?
Please review this paper.
user
Title: Ustekinumab trough levels predicting laboratory and endoscopic remission in patients
with Crohn’s disease
Version: 1 Date: 19 Jan 2022
Reviewer's report:
The authors investigated ustekinumab pharmacokinetics in a single-center cohort of 28 Crohn’s
disease patient. This is another association study between TDM and clinical and endoscopic
outcomes in IBD. Many important data are missing in the methods section and the endoscopic
scoring system used is not adapted for assessing CD activity out of the screening for
postoperative recurrence.
It is not understandable why the authors have chosen the Rutgeerts score for assessing CD
endoscopic activity as this score was only made for postoperative recurrence. I suggest to use
CDEIS or SES-CD as recommended by all CD guidelines and redo the statistical analysis.
What were the selection criteria for participating in this study?
Can you give some information about the study design: at least when and how these patients
have been recruited?
assistant